Annual Report & Financial Statements

AI SummaryClose X

Coiled Therapeutics plc, formerly Roquefort Therapeutics plc, has released its audited results for the year ended December 31, 2025, detailing a significant strategic shift towards clinical-stage oncology assets. The company successfully acquired worldwide rights to the clinical-stage oncology asset AO-252 and raised £8.5 million in gross proceeds to fund its development through key clinical milestones. Following positive early data showing an 80% Clinical Benefit Rate with a twice-daily dosing regimen, Coiled Therapeutics is accelerating its transition into dose expansion cohorts for ovarian and prostate cancers, with data readouts anticipated in the second half of 2026. The company also strengthened its board and completed a listing on the AIM market of the London Stock Exchange.

Disclaimer*

UK 100

Latest directors dealings